乳腺癌筛查间隔对晚期诊断率与总生存的影响
该研究利用机构乳腺数据平台纳入2004–2019年8145例有诊断前筛查史的新发乳腺癌患者,按筛查间隔分为每年、每两年、间断和基线组。结果显示晚期癌比例随筛查间隔延长而升高,每年、每两年和间断组分别为9%、14%和19%(P<.001);每两年和间断组总生存较每年组更差,校正潜在领先时间后相对风险仍升高。作者认为每年乳腺X线筛查与较低晚期癌风险和更好总生存相关,并建议40岁及以上女性每年筛查。
要点
- 每年、每两年和间断筛查组晚期癌比例分别为9%、14%和19%(P<.001)。
- 每两年和间断组总生存较每年组更差,相对风险分别为1.42和2.69。
- 校正潜在领先时间后,每两年和间断组相对风险分别为1.39和2.01。
核心结论
- 每年乳腺X线筛查与较低晚期癌风险和更好总生存相关,且该关联在不同临床和人口学亚组中一致。
- 作者认为40岁及以上女性每年筛查有获益。
研究设计与样本
- 利用机构乳腺研究数据平台识别2004–2019年间有乳腺癌新诊断登记记录且有诊断前筛查史的患者。
- 共纳入8145例有诊断前乳腺X线筛查的乳腺癌患者。
- 筛查间隔定义:每年为≤15个月,每两年为>15且≤27个月,间断为>27个月,基线为仅有一次诊断前筛查。
- 主要终点为晚期癌(TNM IIB期或更差),次要终点为总生存。
- 采用多变量逻辑回归分析筛查间隔与晚期癌的关联,采用比例风险回归进行生存分析,并利用固定时间点生存分析评估潜在领先时间。
主要发现
- 晚期癌诊断比例随筛查间隔延长而显著升高,每年、每两年和间断组分别为9%、14%和19%(P<.001)。
- 该趋势不受年龄、种族和绝经状态影响。
- 每两年和间断组总生存较每年筛查组更差,相对风险分别为1.42(95%CI 1.11–1.82)和2.69(95%CI 2.11–3.43)。
- 校正潜在领先时间后,每两年和间断组相对风险分别为1.39(95%CI 1.08–1.78)和2.01(95%CI 1.58–2.55)。
关键数值与推荐
- 晚期癌比例:每年组9%、每两年组14%、间断组19%(P<.001)。
- 总生存相对风险:每两年组1.42(95%CI 1.11–1.82),间断组2.69(95%CI 2.11–3.43)。
- 校正潜在领先时间后总生存相对风险:每两年组1.39(95%CI 1.08–1.78),间断组2.01(95%CI 1.58–2.55)。
临床怎么用
- 作者认为40岁及以上女性每年筛查有获益,该结论来自本研究结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Controversy continues regarding the effect of screening mammography on breast cancer outcomes. We evaluated late-stage cancer rate and overall survival (OS) for different screening intervals using a real-world institutional research data mart. METHODS: Patients having both a cancer registry record of new breast cancer diagnosis and prediagnosis screening history between 2004 and 2019 were identified from our institutional research breast data mart. Time interval between the two screening mammograms immediately preceding diagnosis and the time to cancer diagnosis were determined. Screening interval was deemed annual if ≤15 months, biennial if >15 and ≤27 months, intermittent if >27 months, and baseline if only one prediagnosis screen was known. The primary end point was late-stage cancer (TNM stage IIB or worse), and the secondary end point was OS. The association of screening interval and late-stage cancer was analyzed using multivariable logistic regression adjusting for prediagnosis characteristics. Proportional hazards regression was used for survival analysis. Potential lead time was analyzed using survival from a uniform fixed time point. RESULTS: In total, 8,145 patients with breast cancer had prediagnosis screening mammography in the timeframe. The percentage of late-stage cancers diagnosed increased significantly with screening interval with 9%, 14%, and 19% late stages for annual, biennial, and intermittent groups (P < .001), respectively. The trend persisted regardless of age, race, and menopausal status. Biennial and intermittent groups had substantially worse OS than the annual screened group, with relative hazards of 1.42 (95% CI, 1.11 to 1.82) and 2.69 (95% CI, 2.11 to 3.43), respectively, and 1.39 (95% CI, 1.08 to 1.78) and 2.01 (95% CI, 1.58 to 2.55) after adjustment for potential lead time. CONCLUSION: Annual mammographic screening was associated with lower risk of late-stage cancer and better OS across clinical and demographic subgroups. Our study suggests benefit of annual screening for women 40 years and older.
引用
- Zuley ML, Bandos AI, Duffy SW, et al. Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival. J Clin Oncol. 2024. PMID: 39167740. doi:10.1200/JCO.24.00285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。